HUP0201598A3 - Pharmaceutical composition comprising erythropoietin for modulation of excitable tissue function and their use - Google Patents
Pharmaceutical composition comprising erythropoietin for modulation of excitable tissue function and their useInfo
- Publication number
- HUP0201598A3 HUP0201598A3 HU0201598A HUP0201598A HUP0201598A3 HU P0201598 A3 HUP0201598 A3 HU P0201598A3 HU 0201598 A HU0201598 A HU 0201598A HU P0201598 A HUP0201598 A HU P0201598A HU P0201598 A3 HUP0201598 A3 HU P0201598A3
- Authority
- HU
- Hungary
- Prior art keywords
- erythropoietin
- modulation
- pharmaceutical composition
- tissue function
- excitable tissue
- Prior art date
Links
- 102000003951 Erythropoietin Human genes 0.000 title 1
- 108090000394 Erythropoietin Proteins 0.000 title 1
- 229940105423 erythropoietin Drugs 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1816—Erythropoietin [EPO]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Pain & Pain Management (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Rheumatology (AREA)
- Psychology (AREA)
- Toxicology (AREA)
- Vascular Medicine (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US29093899A | 1999-04-13 | 1999-04-13 | |
US54722000A | 2000-04-11 | 2000-04-11 |
Publications (2)
Publication Number | Publication Date |
---|---|
HUP0201598A2 HUP0201598A2 (en) | 2002-09-28 |
HUP0201598A3 true HUP0201598A3 (en) | 2002-10-28 |
Family
ID=26966493
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HU0201598A HUP0201598A3 (en) | 1999-04-13 | 2000-04-13 | Pharmaceutical composition comprising erythropoietin for modulation of excitable tissue function and their use |
Country Status (21)
Country | Link |
---|---|
EP (1) | EP1171147A4 (en) |
JP (1) | JP2003520194A (en) |
KR (2) | KR100883232B1 (en) |
CN (1) | CN1607957B (en) |
AU (1) | AU784550B2 (en) |
BG (1) | BG65353B1 (en) |
BR (1) | BR0009737A (en) |
CA (1) | CA2383940A1 (en) |
CR (1) | CR6501A (en) |
CZ (1) | CZ20013695A3 (en) |
EA (1) | EA004766B1 (en) |
HU (1) | HUP0201598A3 (en) |
IL (2) | IL145895A0 (en) |
IS (1) | IS6104A (en) |
MX (1) | MXPA01010177A (en) |
NO (1) | NO20014991L (en) |
NZ (4) | NZ545478A (en) |
PL (1) | PL352223A1 (en) |
SK (1) | SK14412001A3 (en) |
TR (2) | TR200103785T2 (en) |
WO (1) | WO2000061164A1 (en) |
Families Citing this family (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19857609A1 (en) | 1998-12-14 | 2000-06-15 | Hannelore Ehrenreich | Use of erythropoietin for the treatment of human cerebral ischemia |
US8236561B2 (en) | 1999-04-15 | 2012-08-07 | Crucell Holland B.V. | Efficient production of IgA in recombinant mammalian cells |
US6855544B1 (en) | 1999-04-15 | 2005-02-15 | Crucell Holland B.V. | Recombinant protein production in a human cell |
US7604960B2 (en) | 1999-04-15 | 2009-10-20 | Crucell Holland B.V. | Transient protein expression methods |
US7297680B2 (en) | 1999-04-15 | 2007-11-20 | Crucell Holland B.V. | Compositions of erythropoietin isoforms comprising Lewis-X structures and high sialic acid content |
WO2003089468A1 (en) * | 2002-04-19 | 2003-10-30 | Crucell Holland B.V. | Methods and means for producing proteins with predetermined post-translational modifications |
US7192759B1 (en) | 1999-11-26 | 2007-03-20 | Crucell Holland B.V. | Production of vaccines |
US7521220B2 (en) | 1999-11-26 | 2009-04-21 | Crucell Holland B.V. | Production of vaccines |
US7527961B2 (en) | 1999-11-26 | 2009-05-05 | Crucell Holland B.V. | Production of vaccines |
AU2001267882A1 (en) | 2000-06-30 | 2002-01-14 | Chugai Seiyaku Kabushiki Kaisha | Preventives and remedies for diseases in association with demyelination |
DE10043457A1 (en) * | 2000-09-04 | 2002-03-28 | Hannelore Ehrenreich | Processes for treating schizophrenia and related psychoses, and using erythropoietin or erythropoietin derivatives to treat schizophrenia and related psychoses |
US20030072737A1 (en) * | 2000-12-29 | 2003-04-17 | Michael Brines | Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs |
PA8536201A1 (en) * | 2000-12-29 | 2002-08-29 | Kenneth S Warren Inst Inc | PROTECTION AND IMPROVEMENT OF CELLS, FABRICS AND ORGANS RESPONDING TO Erythropoietin |
EP1471871B1 (en) * | 2001-02-02 | 2007-05-02 | Ortho-McNeil Pharmaceutical, Inc. | Treatment of neurological dysfunction comprising fructopyranose sulfamates and erythropoietin |
US20030118630A1 (en) * | 2001-12-07 | 2003-06-26 | Anthony Cerami | Immune modulation device for use in animals |
ATE542904T1 (en) | 2001-10-29 | 2012-02-15 | Crucell Holland Bv | METHOD AND MEANS FOR PRODUCING PROTEINS WITH PREDEFINED POST-TRANSLATIONAL MODIFICATIONS |
EP1465987B1 (en) | 2001-12-07 | 2008-01-23 | Crucell Holland B.V. | Production of viruses, viral isolates and vaccines |
AU2003206251B2 (en) * | 2002-01-09 | 2008-03-13 | Crucell Holland B.V. | Use of erythropoietin for the preventive or curative treatment of cardiac failure |
GB0211578D0 (en) * | 2002-05-21 | 2002-06-26 | Univ Belfast | Medicaments |
CA2491567A1 (en) * | 2002-07-01 | 2004-01-08 | The Kenneth S. Warren Institute, Inc. | Recombinant tissue protective cytokines and encoding nucleic acids thereof for protection, restoration, and enhancement of responsive cells, tissues, and organs |
DE10234192B4 (en) * | 2002-07-26 | 2009-11-26 | Epoplus Gmbh Co.Kg | Use of erythropoietin |
US7396913B2 (en) | 2002-10-14 | 2008-07-08 | Abbott Laboratories | Erythropoietin receptor binding antibodies |
WO2004087063A2 (en) * | 2003-03-27 | 2004-10-14 | Janssen Pharmaceutica Nv | Use of erythropoietin in stroke recovery |
US7718363B2 (en) * | 2003-04-25 | 2010-05-18 | The Kenneth S. Warren Institute, Inc. | Tissue protective cytokine receptor complex and assays for identifying tissue protective compounds |
WO2004099396A1 (en) | 2003-05-09 | 2004-11-18 | Crucell Holland B.V. | Cultures of e1-immortalized cells and processes for culturing the same to increase product yields therefrom |
DE102004063927A1 (en) * | 2004-01-23 | 2005-12-15 | Epoplus Gmbh Co.Kg | Use of low dose erythropoietin to stimulate endothelial progenitor cells as well as organ regeneration and progression slowing of end organ damage |
AT500929B1 (en) | 2004-11-09 | 2007-03-15 | Medizinische Uni Wien Muw | PHARMACEUTICAL PREPARATION CONTAINING ERYTHROPOIETIN |
CA2618396C (en) * | 2005-08-05 | 2018-02-27 | Warren Pharmaceuticals, Inc. | Tissue protective peptides and uses thereof |
US20070072795A1 (en) * | 2005-09-28 | 2007-03-29 | Anton Haselbeck | Treatment of neurodegenerative disorders |
GB0525540D0 (en) * | 2005-12-15 | 2006-01-25 | Isis Innovation | New treatment |
DE102006004008A1 (en) | 2006-01-27 | 2007-08-02 | Hannelore Prof. Dr. Dr. Ehrenreich | Treating or preventing multiple sclerosis comprises administering erythropoietin for periods separated by intervals in which no erythropoietin is administered |
CN101062407A (en) * | 2006-04-29 | 2007-10-31 | 中国科学院上海生命科学研究院 | Function of erythropoietin in the preventing and treating of retinal injury |
US8133860B2 (en) * | 2006-07-20 | 2012-03-13 | Rosalind Franklin University Of Medicine And Science | Facilitation of resuscitation from cardiac arrest by erythropoietin |
EP2101808A4 (en) * | 2007-01-10 | 2011-11-30 | Edison Pharmaceuticals Inc | Treatment of respiratory chain disorders using compounds having erythropoietin or thrombopoietin activity |
WO2009010107A1 (en) * | 2007-07-19 | 2009-01-22 | Hannelore Ehrenreich | Use of epo receptor activation or stimulation for the improvement of the edss score in patients with multiple sclerosis |
JP5542064B2 (en) | 2008-01-22 | 2014-07-09 | アライム ファーマシューティカルズ,インコーポレーテッド | Tissue protective peptides and peptide analogs to prevent and treat diseases and disorders associated with tissue damage |
RU2519695C2 (en) * | 2010-07-21 | 2014-06-20 | Олег Ильич Эпштейн | Medication for treating attention deficit disorder and method of treating attention deficit disorder |
CN111066727B (en) * | 2019-12-20 | 2021-08-27 | 中国人民解放军陆军军医大学 | Method for constructing mouse model of action mechanism in permeability of hypoxic blood testis barrier |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6197229A (en) * | 1984-10-18 | 1986-05-15 | Chugai Pharmaceut Co Ltd | Stable erythropoietin preparation |
US5614184A (en) * | 1992-07-28 | 1997-03-25 | New England Deaconess Hospital | Recombinant human erythropoietin mutants and therapeutic methods employing them |
US5661125A (en) * | 1992-08-06 | 1997-08-26 | Amgen, Inc. | Stable and preserved erythropoietin compositions |
US20020052309A1 (en) * | 1996-09-11 | 2002-05-02 | Athanasius A. Anagnostou | Method of treating endothelial injury |
DE19857609A1 (en) * | 1998-12-14 | 2000-06-15 | Hannelore Ehrenreich | Use of erythropoietin for the treatment of human cerebral ischemia |
-
2000
- 2000-04-13 TR TR2001/03785T patent/TR200103785T2/en unknown
- 2000-04-13 CA CA002383940A patent/CA2383940A1/en not_active Abandoned
- 2000-04-13 NZ NZ545478A patent/NZ545478A/en not_active IP Right Cessation
- 2000-04-13 EP EP00923344A patent/EP1171147A4/en not_active Ceased
- 2000-04-13 JP JP2000610496A patent/JP2003520194A/en active Pending
- 2000-04-13 TR TR2004/02194T patent/TR200402194T2/en unknown
- 2000-04-13 CZ CZ20013695A patent/CZ20013695A3/en unknown
- 2000-04-13 NZ NZ560696A patent/NZ560696A/en not_active IP Right Cessation
- 2000-04-13 WO PCT/US2000/010019 patent/WO2000061164A1/en active IP Right Grant
- 2000-04-13 NZ NZ514690A patent/NZ514690A/en not_active IP Right Cessation
- 2000-04-13 BR BR0009737-3A patent/BR0009737A/en not_active Application Discontinuation
- 2000-04-13 CN CN008087466A patent/CN1607957B/en not_active Expired - Lifetime
- 2000-04-13 AU AU43487/00A patent/AU784550B2/en not_active Expired
- 2000-04-13 PL PL00352223A patent/PL352223A1/en not_active Application Discontinuation
- 2000-04-13 MX MXPA01010177A patent/MXPA01010177A/en active IP Right Grant
- 2000-04-13 EA EA200101073A patent/EA004766B1/en not_active IP Right Cessation
- 2000-04-13 SK SK1441-2001A patent/SK14412001A3/en not_active Application Discontinuation
- 2000-04-13 KR KR1020017013093A patent/KR100883232B1/en not_active IP Right Cessation
- 2000-04-13 IL IL14589500A patent/IL145895A0/en unknown
- 2000-04-13 HU HU0201598A patent/HUP0201598A3/en unknown
- 2000-04-13 NZ NZ533098A patent/NZ533098A/en not_active IP Right Cessation
- 2000-04-13 KR KR1020077021154A patent/KR101012932B1/en not_active IP Right Cessation
-
2001
- 2001-10-11 IS IS6104A patent/IS6104A/en unknown
- 2001-10-11 IL IL145895A patent/IL145895A/en not_active IP Right Cessation
- 2001-10-12 NO NO20014991A patent/NO20014991L/en not_active Application Discontinuation
- 2001-10-26 BG BG106058A patent/BG65353B1/en unknown
- 2001-11-13 CR CR6501A patent/CR6501A/en not_active Application Discontinuation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HUP0201598A3 (en) | Pharmaceutical composition comprising erythropoietin for modulation of excitable tissue function and their use | |
IL147217A0 (en) | New spirooxindole derivatives and pharmaceutical compositions containing the same for treatment of pain | |
HUP0200588A2 (en) | Diaryl derivatives and pharmaceutical compositions containing them and their use | |
HUP0103874A3 (en) | Use of antibiotics and pharmaceutical compositions comprising thereof | |
HUP0203939A3 (en) | Pharmaceutical compounds and compositions containing them and their use | |
HUP0200831A2 (en) | Novel pharmaceutical composition containing amoxycillin and its use | |
IL147308A0 (en) | Compounds for the modulation of pparγ activity and pharmaceutical compositions containing the same | |
PL354168A1 (en) | Pharmaceutical composition of nateglinide and another antidiabetcagent | |
AU1515901A (en) | Implant consisting of bone material | |
HUP0200548A2 (en) | Pharmaceutical compositions and their use | |
HUP0001541A3 (en) | Phthalazinone derivatives and pharmaceutical compositions containing them | |
HUP0202862A3 (en) | Pharmaceutical composition containing novel combination of loteprednol and antihistamines | |
ZA986437B (en) | Derivatives of acyl-piperazinyl-pyrimidines their preparation and application as medicaments | |
AU5880498A (en) | New benzolactam derivatives and medicinal compositions containing the same | |
HUP0203935A3 (en) | Sulfonamides and derivatives thereof that modulate the activity of endothelin, pharmaceutical compositions containing them and their use | |
HU9800147D0 (en) | Isoxasol-and crotonoil-amide derivatives and pharmaceutical and diagnostical compositions containing them | |
HUP0001858A3 (en) | Bi-aromatic compounds and pharmaceutical and cosmetic compositions containing same and the use of the compounds | |
AU7651100A (en) | Pharmaceutical and/or cosmetical compositions | |
HUP0102025A3 (en) | Derivatives of 1,3,4-oxadiazolone, pharmaceutical compositions containing them and their use | |
IL136612A0 (en) | Phenylaminoalkylcarboxylic acid derivatives and medical compositions containing the same | |
HUP0101733A3 (en) | Pharmaceutical compositions containing sulfonyl-dipeptides and their use | |
IL126734A0 (en) | Cosmetic and/or pharmaceutical and/or dermatological compositions | |
HUP0003074A3 (en) | Pharmaceutical composition comprising ssri and betha-blocking agent | |
HUP0202753A3 (en) | Pharmaceutical compositions containing novel combination of loteprednol and b2-adrenoceptor agonists and their use | |
AU6866700A (en) | Biscyclopropanecarboxylic acid amide compounds and medicinal use thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FD9A | Lapse of provisional protection due to non-payment of fees |